Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year, » Read more about: Massive Upside In Big Money Pharma Favorite? »
Read More
3 Must-See Entertainment Stocks for Your Portfolio
[1] Disney
The Walt Disney Company is known for its ability to create high-quality, imaginative content that appeals to people of all ages. From classic films to modern franchises, Disney has a reputation for producing stories and characters that are beloved by many.
However, the company’s appeal extends beyond its enchanting brand.
» Read more about: 3 Must-See Entertainment Stocks for Your Portfolio »
Read More
1 Inflation-Beating Stock That Passes Buffett’s Test
In times of uncertainty, it can be helpful to tap into the wisdom of Warren Buffett, who was active in the market during the last time inflation was this high in the early 1980s. In his 1982 letter to shareholders, Buffett pointed out that businesses that excel in inflationary environments have two key qualities.
First,
» Read more about: 1 Inflation-Beating Stock That Passes Buffett’s Test »
Read More
Sayonara Carvana
Carvana’s revenue rose 101% in 2019, grew 42% in 2020, even as the COVID-19 pandemic disrupted traditional dealerships, and soared 129% in 2021.
However, in the first nine months of 2022, Carvana’s revenue only grew 19% year-over-year to $10.8 billion, as the market demand for used vehicles cooled off. Despite this slowdown in growth,
» Read more about: Sayonara Carvana »
Read More
1 Cloud SaaS Healthcare Stock to Buy on the Dip?
It might surprise many that Veeva Systems Inc. (NYSE:VEEV), best known for its cloud-based software solutions tailored to the life sciences industry, has maintained a core principle of putting customer success and product excellence ahead of short-term gains.
In a market crowded with SaaS companies seeking to serve a wide variety of enterprises,
» Read more about: 1 Cloud SaaS Healthcare Stock to Buy on the Dip? »
Read MoreThe Ivy
2 Stocks To Count On For Next Decade
Trade wars and tariffs are taking their toll but that also translates to opportunity among some quality names that have taken a hit, such as Dutch Bros. Even after a market dip, the share price is still up 14% this year, far outpacing the broader market.
The relative outperformance stems from Dutch Bros’
» Read more about: 2 Stocks To Count On For Next Decade »
Read MoreThe Spotlight
Spotlight: What to Buy If Things Get Crazy Soon
Among the first lessons any great investor learns is “Don’t Fight The Fed.” Simply put, it means when the Fed is accommodative and engaging in quantitative easing, money is cheap and economies boom. Some call this the Fed Put because as markets fall, the Federal Reserve acts swiftly to provide liquid support by buying bonds.
» Read more about: Spotlight: What to Buy If Things Get Crazy Soon »
Read MoreThe Daily
The Wall Street gift guide: What bankers are asking for this holiday season
And despite the wellness boom on Wall Street — and many other corners of the corporate world — alcohol is still a go-to option. None of the survey respondents said they wanted booze for themselves, but Eileen Rizzo, the CEO of Zachys Wine and Liquor, said it’s a popular gift.
» Read more about: The Wall Street gift guide: What bankers are asking for this holiday season »